Curasan AG

euro adhoc: Earnings Forecast
curasan AG: Profit forecast following sale of dental division

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.


Kleinostheim, June 11, 2008 - Curasan AG (ISIN: DE 000 549 453 8), listed in the Prime Standard, has sold its dental division to Riemser Arzneimittel AG, Greifswald, effective from July 1, 2008.

The earnings expected therefrom will amount to a minimum of EUR 15 million and will generate significant one-time income at the end of the 2008 financial year.

In addition to inventories, the acquirer will take over all intangible assets attributable to the dental division including the licences for REVOIS® and Cerasorb®. Furthermore, all shares held in curasan Inc., USA, as well as part of the workforce will be transferred to the acquirer.

Curasan AG will remain the manufacturer of the principal product, Cerasorb®. The company will continue to develop new synthetic bone regeneration materials and other products for regenerative medicine and supply these to Riemser Arzneimittel AG as well as to distribution partners for other fields of indication not associated with the dental market. All patents and patent filings relating to Cerasorb® will remain with curasan AG.

About curasan AG: Exchange-listed curasan AG (ISIN DE 000 549 453 8) is a leading innovator within the market of bone and tissue regeneration. Alongside its synthetic bone regeneration material Cerasorb®, the company has established a future-oriented product pipeline. Several new developments will be ready for market rollout in the coming years and are to be distributed within various market segments via well-positioned sales partners.

About RIEMSER Arzneimittel AG: RIEMSER Arzneimittel AG is a medium-sized pharmaceutical company with its own research facilities. Headquartered in Greifswald (island of Riems), Western Pomerania, the stock corporation operates several sites in Germany. RIEMSER produces and markets modern active ingredients, pharmaceuticals and dental products for various areas of application in human and veterinary medicine. Its products are distributed worldwide.

end of announcement                               euro adhoc

Further inquiry note:

Information hotline
An e-mail information hotline will be put in place for shareholders and
investors on Wednesday, June 11 from 12:00 to 13:00 hrs (CET). During this
period, your questions should be forwarded to

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade

Original-Content von: Curasan AG, übermittelt durch news aktuell

Weitere Meldungen: Curasan AG

Das könnte Sie auch interessieren: